ARID4B and type 2 diabetes mellitus: Interestingly, in humans, Tirzepatide treatment reduced BCAA, BCKA and other BCAA-derived metabolites in plasma, including 3-HIB and 2-HB, previously shown to associate with insulin resistance and T2D [238].